Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
about
Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammationPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironConsiderations and challenges in defining optimal iron utilization in hemodialysisIntravenous iron therapy: how far have we come?Safety of intravenous iron in hemodialysis patients.Ferumoxytol for the treatment of iron deficiency.Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.Iron and infection in hemodialysis patientsPostoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement.Iron therapy for renal anemia: how much needed, how much harmful?A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.Intravenous iron therapy: well-tolerated, yet not harmless.Iron metabolism and iron supplementation in cancer patientsA randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.Risk of infection with intravenous iron therapy.Safety issues with intravenous iron products in the management of anemia in chronic kidney diseaseAnemia of critical illness.Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).Iron inhibits respiratory burst of peritoneal phagocytes in vitro.Predicting Quality of Life Changes in Hemodialysis Patients Using Machine Learning: Generation of an Early Warning System.Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up.The comparative safety of various intravenous iron preparations in chronic kidney disease patients.Intravenous Irons: From Basic Science to Clinical Practice
P2860
Q26830874-29580AC3-2B3C-4AA3-A28E-77A7B0164872Q27004170-6300A981-2C39-49BB-800B-F80BFB925997Q28088564-E0423D87-5354-41DB-8D24-12EF2BC6FD4DQ28276678-F9A7DF5A-53DC-44F1-BC07-266042562B62Q30234981-727454DC-D7DE-4954-A57A-5E8C5E95F773Q30454001-F76F52B5-7099-4FD6-A58C-1064636AC741Q33279821-E70ADF28-98E9-4029-9FD6-198461083ABDQ33591327-A4704B3A-62AF-4103-A636-CC42E471E5DCQ34385089-F923F55D-EE5C-4FA9-B84F-89E031D87253Q35650627-3679E0BF-06E5-4636-AFE9-EDD7C5A87E1CQ35998091-06AAD879-3AA5-4CFC-A85D-66AAD4BCC348Q36310902-8EC99A90-3A60-4956-9170-3D537848BD08Q36371665-AB34BCBB-D852-48C0-AA33-D47031D6FE63Q36722337-664AAD71-C80D-49ED-8BCE-2084DBCD57F1Q36897822-C087846D-EC51-4372-BF1B-36F35087AF59Q37161960-3DC90895-4592-4794-92C6-9D4AAE5C6DF1Q37281589-63E8183D-03A7-4BAE-9254-822B40461CE0Q37587226-68B4DE8F-0558-4402-A628-27FC98409633Q38245887-419337A1-BA34-4EFA-8641-129E1076A63CQ39132837-27EDC885-5879-49B9-BCE3-00EE98CEFBD0Q39749336-A5FA6718-0B4A-4E14-BF58-6A84F5014555Q45943428-6618D1DB-01E6-4750-BC9C-E840BED5500CQ46062433-344F4ED6-6345-40B7-A9EC-8BE58BDB52E6Q46459696-00394C5C-32F2-440F-B313-467DCD4AB06EQ57167424-E708B891-399C-4DEC-B875-1E63D133023C
P2860
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@en
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@nl
type
label
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@en
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@nl
prefLabel
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@en
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@nl
P2093
P1433
P1476
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
@en
P2093
Anthony Wolfe
Chaim Charytan
David Van Wyck
George R Aronoff
J Phillip Pennell
James Strom
Marcos Rothstein
Samuel Blumenthal
P304
P356
10.1111/J.1523-1755.2004.00872.X
P407
P577
2004-09-01T00:00:00Z
P5875
P6179
1012449971